OS Therapies Statistics
Total Valuation
OS Therapies has a market cap or net worth of $84.32 million. The enterprise value is $82.46 million.
| Market Cap | 84.32M |
| Enterprise Value | 82.46M |
Important Dates
The next estimated earnings date is Saturday, February 15, 2025, before market open.
| Earnings Date | Feb 15, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
OS Therapies has 21.24 million shares outstanding. The number of shares has decreased by -6.42% in one year.
| Current Share Class | 21.24M |
| Shares Outstanding | 21.24M |
| Shares Change (YoY) | -6.42% |
| Shares Change (QoQ) | +165.35% |
| Owned by Insiders (%) | 17.56% |
| Owned by Institutions (%) | 0.75% |
| Float | 16.87M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 472.36 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.76
| Current Ratio | 0.76 |
| Quick Ratio | 0.72 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.13 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -237.78% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.85M |
| Employee Count | 4 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 2.72 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 59.85 |
| Average Volume (20 Days) | 110,274 |
Short Selling Information
The latest short interest is 8,931, so 0.04% of the outstanding shares have been sold short.
| Short Interest | 8,931 |
| Short Previous Month | n/a |
| Short % of Shares Out | 0.04% |
| Short % of Float | 0.05% |
| Short Ratio (days to cover) | 0.01 |
Income Statement
| Revenue | n/a |
| Gross Profit | -5,154 |
| Operating Income | -5.00M |
| Pretax Income | n/a |
| Net Income | -7.42M |
| EBITDA | -5.00M |
| EBIT | -5.00M |
| Earnings Per Share (EPS) | -$0.76 |
Balance Sheet
| Cash & Cash Equivalents | 1.86M |
| Total Debt | n/a |
| Net Cash | 1.86M |
| Net Cash Per Share | $0.09 |
| Equity (Book Value) | -707,127 |
| Book Value Per Share | -0.03 |
| Working Capital | -613,787 |
Cash Flow
In the last 12 months, operating cash flow was -$5.78 million and capital expenditures $19, giving a free cash flow of -$5.78 million.
| Operating Cash Flow | -5.78M |
| Capital Expenditures | 19 |
| Free Cash Flow | -5.78M |
| FCF Per Share | -$0.27 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
OS Therapies does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 6.42% |
| Shareholder Yield | 6.42% |
| Earnings Yield | -8.80% |
| FCF Yield | -6.85% |
Analyst Forecast
The average price target for OS Therapies is $14.50, which is 265.24% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $14.50 |
| Price Target Difference | 265.24% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |